In ,a recent media release, Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify® or more commonly just “PyL”) as a PSMA-based PET imaging agent for identification of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: imaging, PET scan, PyL, Pylarify | 16 Comments »
Yesterday the US Food and Drug Administration (FDA) gave its approval for the first gallium-68 prostate-specific membrane antigen imaging agent (Ga-67 PSMA-11), for the use in association with positron emission tomography (PET) scanning for the evaluation of men with suspected prostate cancer — and most particularly for those men with high-risk characteristics suggesting the possibility of metastasis, including men with newly diagnosed or recurrent disease. However, here’s the “but”… READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: gallium-68, imaging, PET, PSMA, scan | 5 Comments »
Members of the Coalition for Biomedical Imaging and Bioengineering Research (CIBR) are interested in patient perspectives and experiences in relation to imaging in the diagnosis, work-up, and management of men with or suspected of having prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: imaging, survey | 1 Comment »
We had previously reported on a presentation by Calais et al. earlier this year. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: Axumin, fluciclovine, fluorine-18, gallium-68, imaging, PET/CT, PSMA, scan | 9 Comments »
A media release issued yesterday by Progenics Pharmaceuticals states that the investigational imaging agent 18F-DCFPyL changed physician behavior in the management of biochemically recurrent prostate cancer in > 65 percent of patients. … READ MORE …
Filed under: Uncategorized | Tagged: 18F-DCFPyL, biochemical, change, CT, imaging, Management, PET, recurrence, scan | Leave a comment »
In a media release issued earlier this morning, Progenics Pharmaceuticals has announced the outcome of a Phase II/III trial of their proprietary, PSMA-targeted imaging agent PyL (also known as 18F-DCFPyL) for identification of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 18F-DCFPyL, imaging, PET, PSMA, PyL | 8 Comments »
Early this morning, Progenics Pharmaceuticals announced completion of enrollment of patients in the Phase II/III OSPREY trial of a new PSMA-targeted PET/CT imaging agent for detection of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: imaging, OSPREY, Progenics, PSMA, PyL | 1 Comment »
Nearly 30 years ago, when your sitemaster first attended a prostate cancer meeting (in 1989) related to the upcoming approval of a new drug called flutamide, he doesn’t remember there being a single clinician at the meeting who was female — out of the 150 or so urologists and medical oncologists who had been invited. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, Diagnosis, future, imaging, research, Treatment | 6 Comments »
A group of Italian researchers have apparently shown that a copper-64 dichloride-based radiotracing agent (64CuCl2) is better than currently-used 18FCl radiotracers in the detection of biochemically recurrent prostate cancer with PET/CT scans … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: copper-64, imaging, PET/CT, radiotracer, scan | 3 Comments »
So for those currently dissatisfied with the capabilities of 1.5 T and 3 T MRI imaging technology, the US Food and Drug Administration has just approved a 7 T MRI device called a “Siemens Magnetom Terra”. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: 7-T, imaging, MRI | Leave a comment »
Dr. Zachary Klaassen and UroToday have provided us with four more interesting summaries of presentations by faculty at the European Association for Urology (EAU)’s meeting in Vienna last weekend. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biomarkers, care, focal, functional, genomics, imaging, molecular, patient-centered, therapy | 4 Comments »
Two recent papers by Sabouri et al. have suggested that a new MRI techique known as “luminal water imaging” may be able to improve the ability of MR scans to identify and grade prostate cancer prior to biopsy. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, fraction, imaging, luminal, MRI, staging, water | 2 Comments »
A new paper in the Journal of Nuclear Medicine has reported the first use of [11C]sarcosine in combination with PET/CT scanning as a technique for imaging prostate cancer in man. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: carbon-11, imaging, PET/CT, sarcosine, scan | Leave a comment »
Our next CureTalks program will be on the evolving role of imaging in the diagnosis and management of prostate cancer on Thursday, July 27, at 5:00 p.m. Pacific / 8:00 p.m. Eastern time. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: CureTalk, imaging, Westphalen | Leave a comment »
